AUSTIN, TX & DURHAM, NC, April 01, 2024 Shattuck Labs, Inc. , a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic.
- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine in frontline Higher-Risk Myelodysplastic Syndromes and frontline TP53 mutant.
AUSTIN, TX and DURHAM, NC, Feb. 13, 2024 Shattuck Labs, Inc. , a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic.
AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 Shattuck Labs, Inc. , a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic.